• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar's Italian Subsidiary

    3/30/21 8:30:00 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAGX alert in real time by email

    Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer

    SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company supports the selection of the investment bank and nominated advisor ("NOMAD") made by the lead sponsor of the planned Dragon special purpose acquisition company (the "Dragon SPAC"). The Dragon SPAC anticipates listing on AIM Italia and merging with its named target, Napo EU S.p.A. ("Napo EU"), the Company's Italian subsidiary.

    Additional information on the Dragon SPAC's banking engagement, including the Dragon SPAC's selection of its required NOMAD, will be issued after the upcoming holidays, during the week of April 5th. A NOMAD is a required financial services firm that will assist and support the issuer, the Dragon SPAC, in ensuring compliance with Borsa Italiana's IPO process for listing on AIM Italia.

    Regarding development and commercialization of crofelemer for COVID-related diarrhea, the subject of an exclusive license from Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned U.S. subsidiary, to Napo EU for the European marketplace (excluding Russia), Napo team members had a scientific advice consultation meeting with a European Union regulatory authority on March 15, 2021. The consensus from the meeting is that diarrhea in infected COVID patients is a recognized unmet need in the EU, which means diarrhea treatment in this patient population would be eligible for the European Medicines Agency's conditional marketing authorization pathway. Such a conditional approval pathway would provide a fast-track application review process during public health emergencies. The regulatory authority requested that Napo develop a clinical protocol synopsis for a placebo-controlled trial in infected COVID-19 patients for their review, which the Company has submitted.

    The March 15, 2021 meeting with the regulatory authority also resulted in confirmation that safety and efficacy data from Napo's approved US New Drug Application (NDA) for crofelemer (Mytesi®) for the drug's FDA-approved indication in the US for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy may be included in Napo's planned conditional approval application for an equivalent indication in the EU.

    About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
    Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

    For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

    About Mytesi®
    Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

    Forward-Looking Statements
    Certain statements in this press release constitute "forward-looking statements." These include statements regarding the Company's expectation that the Dragon SPAC will list on AIM Italia and merge with Napo EU, and the expectation that additional information on the Dragon SPAC's banking engagement, including the Dragon SPAC's selection of its required NOMAD, will be issued during the week of April 5, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    Contact:
    Peter Hodge
    Jaguar Health, Inc.
    [email protected]
    Jaguar-JAGX

    SOURCE: Jaguar Health, Inc

    Get the next $JAGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JAGX

    DatePrice TargetRatingAnalyst
    7/7/2021$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $JAGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer King Steven R. converted options into 1 shares, increasing direct ownership by 0.69% to 145 units (SEC Form 4)

      4 - Jaguar Health, Inc. (0001585608) (Issuer)

      5/20/25 5:05:04 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Conte Lisa A converted options into 2 shares, increasing direct ownership by 0.30% to 666 units (SEC Form 4)

      4 - Jaguar Health, Inc. (0001585608) (Issuer)

      5/20/25 5:00:07 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Micek John

      4 - Jaguar Health, Inc. (0001585608) (Issuer)

      4/2/25 8:10:19 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAGX
    SEC Filings

    See more
    • Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Jaguar Health, Inc. (0001585608) (Filer)

      5/22/25 6:23:27 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Jaguar Health Inc.

      424B5 - Jaguar Health, Inc. (0001585608) (Filer)

      5/21/25 9:44:54 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Jaguar Health Inc.

      424B5 - Jaguar Health, Inc. (0001585608) (Filer)

      5/21/25 7:31:22 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Jaguar Health Inc.

      SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)

      7/22/24 4:10:52 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jaguar Health Inc. (Amendment)

      SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)

      6/10/24 11:26:28 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Jaguar Health Inc.

      SC 13G - Jaguar Health, Inc. (0001585608) (Subject)

      12/29/23 11:09:37 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $JAGX
    Leadership Updates

    Live Leadership Updates

    See more

    $JAGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $JAGX
    Financials

    Live finance-specific insights

    See more
    • Cantor Fitzgerald initiated coverage on Jaguar Health with a new price target

      Cantor Fitzgerald initiated coverage of Jaguar Health with a rating of Overweight and set a new price target of $5.00

      7/7/21 6:37:12 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

      FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals."Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We ar

      9/10/24 10:00:00 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

      Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy."Cathy Collis was instrumental in bringing about the Gelclair in-license agreement. She is a results-oriented commercial leader with more than 25 years of experience in the biopharmaceutical industry, and

      4/18/24 8:30:00 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

      Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S.Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium priceSAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr

      4/2/24 8:30:00 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

      MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

      5/20/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

      MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

      3/26/25 7:00:00 AM ET
      $AEMD
      $ASPI
      $ATCH
      $BNRG
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • Jaguar Health Reports 2020 Financial Results and Business Updates

      Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year. In 2020, the Company's animal product research and development efforts were intentionally minimal, and Jaguar's animal-related sales were also minimal.

      3/31/21 4:15:00 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care